QAD (NASDAQ:QADA)'s stock had its "neutral" rating restated by investment analysts at Sidoti in a report issued on Wednesday, Benzinga reports. They currently have a $77.00 price objective on the software maker's stock. Sidoti's price target suggests a potential downside of 0.81% from the company's previous close.
QADA has been the topic of a number of other reports. Zacks Investment Research raised shares of QAD from a "sell" rating to a "hold" rating in a report on Thursday, February 18th. TheStreet raised shares of QAD from a "c+" rating to a "b" rating in a research note on Monday, April 5th. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of "Buy" and a consensus target price of $56.50.
NASDAQ QADA opened at $77.63 on Wednesday. QAD has a 52 week low of $37.02 and a 52 week high of $78.95. The company has a market cap of $1.61 billion, a PE ratio of 485.22 and a beta of 1.32. The company has a quick ratio of 1.57, a current ratio of 1.57 and a debt-to-equity ratio of 0.10. The firm's 50-day simple moving average is $68.68 and its two-hundred day simple moving average is $59.54.
QAD (NASDAQ:QADA) last announced its quarterly earnings results on Tuesday, March 23rd. The software maker reported $0.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.21 by $0.38. QAD had a net margin of 1.08% and a return on equity of 3.21%. The firm had revenue of $82.98 million for the quarter, compared to the consensus estimate of $78.12 million. As a group, equities research analysts anticipate that QAD will post 0.09 EPS for the current year.
Hedge funds have recently made changes to their positions in the stock. Marshall Wace North America L.P. purchased a new stake in QAD in the first quarter worth $41,000. Arizona State Retirement System purchased a new position in QAD during the fourth quarter valued at $220,000. State Board of Administration of Florida Retirement System purchased a new position in QAD during the fourth quarter valued at $241,000. JPMorgan Chase & Co. lifted its position in QAD by 10.8% during the third quarter. JPMorgan Chase & Co. now owns 4,309 shares of the software maker's stock valued at $181,000 after buying an additional 421 shares during the period. Finally, Morgan Stanley lifted its position in QAD by 5.3% during the third quarter. Morgan Stanley now owns 7,642 shares of the software maker's stock valued at $323,000 after buying an additional 385 shares during the period. 47.03% of the stock is owned by institutional investors.
QAD Inc provides cloud-based enterprise software solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers various software solutions, such as customer and service management solutions for manufacturers to acquire new customers; manufacturing solutions, which supports manufacturing business processes; enterprise asset management to manage, maintain, and install capital equipment; supply chain execution solutions that provides tools to support inventory and warehouse management; and financials solutions to manage and control finance and accounting processes.
See Also: Lock-Up Period Expiration
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: Can individual investors take part in an IPO?7 Healthcare Stocks Delivering Innovation in 2021
We all knew that traditional healthcare services were disrupted in 2020. The patient-doctor relationship went virtual. In the early months of the pandemic, many people in need of elective surgeries simply did not have that option available to them. And even local pharmacies took on a new e-commerce role as curbside pickup or home delivery of prescription medication became the norm.
Not surprisingly healthcare stocks were battered last year. Overall, the sector was down 11%, far below the S&P 500 Index that climbed over 15%.
However, the market is always forward-looking with a particular eye towards innovation. The healthcare sector has many companies that are developing innovative approaches in areas such as gene editing. And other companies are in late-stage trials for drugs that can deliver breakthrough results for conditions that continue to plague our world.
That’s the focus of this presentation. We’ve identified 7 healthcare stocks that are delivering innovative ideas that will help deliver better patient outcomes. And in some cases will revolutionize medicine altogether. These are also the stocks that analysts have their eye on.
View the "7 Healthcare Stocks Delivering Innovation in 2021"